UB Spinoff Could Cut Resources Needed to Test Drug Safety in Half

Updated September 3, 2015 This content is archived.

Cytocybernetics, a company founded by Glenna C. Bett, PhD, associate professor of obstetrics and gynecology, and Randall L. Rasmusson, PhD, professor of physiology and biophysics, has created new technology that could cut the amount of money and time needed for preclinical drug trials in half. The company has attracted approximately $291,000 in funding.